CRBGCorebridge Financial
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $1.22In line
- vs $1.22 expected on Nov 2
- Stock move on it
- +2.00%
- one session
- Typical move
- ±1.7%
- average over 2 reports
- Price
- $35.98
- −0.39% today · $14.2B cap
Past and upcoming reports
2
| Nov 2, 2026 | Sep 30, 2026 | Time not given | $1.22 | $1.22 | +2.00% |
| Aug 3, 2026 | Jun 30, 2026 | Time not given | $1.20 | Missed$1.12 | +1.31%2d |
After the report
Aug 3, 2026 report
This covers the Aug 3, 2026 report. The Nov 2, 2026 numbers are in the table above.
Corebridge beat EPS estimates, but revenue recovery remains necessary to validate durability
Corebridge reported $1.12 EPS for the quarter ended June 30, beating the $1.08 estimate by 3.7%. Shares rose 1.25% to $34.01 on August 6, while available data showed no day-specific earnings reaction. The forward thesis depends on revenue recovery, particularly in variable investment income and individual retirement sales.
Reported against expected
BeatReported EPS was $1.12 versus the $1.08 estimate, a $0.04 or 3.7% beat.
Guidance
No explicit forward guidance or quantified guidance change was provided in the payload.
How the stock reacted
Shares gained 1.25% to $34.01 on August 6. event-day, day-one, and day-two reactions were unavailable.
What changed
EPS reached $1.12, beating estimates by 3.7%, while revenue recovery remained unconfirmed.
What the price now assumes
The 1.25% gain to $34.01 suggests measured support, tempered by overbought RSI at 76.59.
What it means for the business
Maintain a conditional thesis. upgrade only if revenue recovery and retirement-sales improvement appear within 30-90 days.
The next one to three months, as we saw it then
Better case35%
The beat becomes durable if revenue recovery broadens and weak variable investment income or retirement sales begin improving.
Base case45%
The EPS beat supports the shares, but the thesis remains valuation-dependent while revenue evidence is incomplete.
Worse case20%
The beat proves temporary if variable investment income and individual retirement sales continue undermining revenue quality.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only after company-specific evidence confirms revenue recovery. no-trade while that evidence remains unavailable.
Scenario odds are a judgement, not measured.